Skip to main content
. Author manuscript; available in PMC: 2010 Aug 4.
Published in final edited form as: Menopause. 2008 Sep–Oct;15(5):832–840. doi: 10.1097/gme.0b013e318169332a

Table 1.

Clinical characteristics of the study participants.

Baseline Study Tx Wk 11 (Saline Study) Tx Wk 12 (Naloxone Study)
ID Age BMI PM E2 FSH %sleep Hf E2 FSH %Slep Hf E2 FSH %Sleep Hf
1 57 20.5 7 20 87 --- --- 17 60 83.8% 3 15 73 83.9% 1
2 53 22.5 4 10 70 77.2% 2 10 76 77.3% 4 11 79 81.1% 4
3 51 29.0 1 22 61 --- --- 17 53 --- --- --- --- ---
4 47 24.9 7 17 65 88% 6 14 63 81.6% 7 17 68 83.0% 3
5 55 23.2 2 12 79 87.6% 5 12 79 83.6% 8 17 87 84.6% 5
6 53 30.0 4 12 61 72.4% 8 23 60 78.2% 9 16 66 71.6% 3
7 54 24.7 1.5 14 60 80.9% 10 12 59 70.7% 9 18 56 87.9% 6

PM = postmenopausal; E2= pg/ml; FSH = mIU/ml; hormone values determined from the 1pm blood sample. Hf = hot flash events recorded on actigraph; % sleep = percent of time spent sleeping during 11pm-7am calculated from actigraph data; unavailable for subject 3 and subject 1 (baseline).